A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Trial Profile

A Phase 3 Randomized, Double Blind Placebo And Naproxen Controlled Multicenter Study Of The Analgesic Efficacy And Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee.

Suspended
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Naproxen; Tanezumab
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Jun 2010 Status changed from recruiting to suspended, as requested by the US FDA due to reports of worsening osteoarthritis, according to a Pfizer media release.
    • 15 Apr 2010 Planned end date changed from May 2010 to Jul 2010 as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top